IN2014KN02324A - - Google Patents
Info
- Publication number
- IN2014KN02324A IN2014KN02324A IN2324KON2014A IN2014KN02324A IN 2014KN02324 A IN2014KN02324 A IN 2014KN02324A IN 2324KON2014 A IN2324KON2014 A IN 2324KON2014A IN 2014KN02324 A IN2014KN02324 A IN 2014KN02324A
- Authority
- IN
- India
- Prior art keywords
- masp
- inhibitory agent
- subject
- amount
- mas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621461P | 2012-04-06 | 2012-04-06 | |
| PCT/US2013/035488 WO2013180834A2 (en) | 2012-04-06 | 2013-04-05 | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02324A true IN2014KN02324A (no) | 2015-05-01 |
Family
ID=49325295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2324KON2014 IN2014KN02324A (no) | 2012-04-06 | 2013-04-05 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20130273053A1 (no) |
| EP (2) | EP2833907B1 (no) |
| JP (3) | JP6366571B2 (no) |
| KR (2) | KR102318623B1 (no) |
| CN (1) | CN104661676A (no) |
| AU (3) | AU2013267909B2 (no) |
| BR (1) | BR112014024793A2 (no) |
| CA (2) | CA2869326C (no) |
| CL (1) | CL2014002694A1 (no) |
| CY (1) | CY1120736T1 (no) |
| DK (2) | DK3366307T3 (no) |
| ES (2) | ES2894944T3 (no) |
| HK (1) | HK1206996A1 (no) |
| HR (1) | HRP20180671T1 (no) |
| HU (1) | HUE036930T2 (no) |
| IL (2) | IL234991B (no) |
| IN (1) | IN2014KN02324A (no) |
| LT (1) | LT2833907T (no) |
| MX (2) | MX2018008658A (no) |
| NO (1) | NO2881536T3 (no) |
| NZ (2) | NZ629675A (no) |
| PL (2) | PL3366307T3 (no) |
| PT (1) | PT2833907T (no) |
| RS (1) | RS57266B1 (no) |
| RU (2) | RU2018114903A (no) |
| SI (1) | SI2833907T1 (no) |
| TR (1) | TR201806939T4 (no) |
| WO (1) | WO2013180834A2 (no) |
| ZA (1) | ZA201408100B (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5891298B2 (ja) * | 2011-05-04 | 2016-03-22 | オメロス コーポレーション | Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物 |
| CN109908352A (zh) * | 2012-06-18 | 2019-06-21 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| AU2014229020B2 (en) * | 2013-03-15 | 2017-09-28 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| CN110177875B (zh) * | 2016-11-28 | 2023-11-28 | 中外制药株式会社 | 包含抗原结合结构域和运送部分的多肽 |
| EP3606965A4 (en) * | 2017-04-03 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MASP-1 ANTIBODIES AND METHODS OF USE |
| CN112867706A (zh) * | 2018-05-29 | 2021-05-28 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| JOP20220011A1 (ar) * | 2019-07-31 | 2023-01-30 | Biocryst Pharm Inc | نظم جرعات لمثبطات عامل متمم d عن طريق الفم |
| IL293550A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| CN114295594B (zh) * | 2021-12-06 | 2023-09-19 | 贵州理工学院 | 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| ATE149841T1 (de) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | Impfstoffe gegen krebs und infektionskrankheiten |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| AU785149B2 (en) * | 1999-12-02 | 2006-10-05 | Jens Christian Jensenius | MASP-3, a complement-fixing enzyme, and uses for it |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7043719B2 (en) * | 2001-07-23 | 2006-05-09 | Intel Corporation | Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations |
| JP4723244B2 (ja) | 2002-07-19 | 2011-07-13 | オメロス コーポレイション | 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料 |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| CN1750844B (zh) * | 2003-02-21 | 2010-09-08 | 健泰科生物技术公司 | 凝集素途径特异性补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
| US20070253949A1 (en) * | 2004-02-03 | 2007-11-01 | Stefan Golz | Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1) |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ATE419671T1 (de) * | 2006-07-31 | 2009-01-15 | Fiat Ricerche | Durch eine fluidströmung betätigbarer elektrischer generator |
| JP5537420B2 (ja) | 2007-05-31 | 2014-07-02 | ユニヴァーシティ オブ ワシントン | 標的遺伝子の誘導性変異誘発 |
| CA2736408A1 (en) * | 2008-09-26 | 2010-04-01 | Roche Glycart Ag | Bispecific anti-egfr/anti-igf-1r antibodies |
| AU2010203712A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| US20120022543A1 (en) * | 2009-03-05 | 2012-01-26 | Smith & Nephew, Inc. | System, method, and apparatus for locating a femoral neck guide wire |
| EP2454281B1 (en) * | 2009-07-17 | 2018-11-14 | Omeros Corporation | Masp isoforms as inhibitors of complement activation |
| AU2010314931A1 (en) * | 2009-11-05 | 2012-06-21 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| KR102217658B1 (ko) * | 2011-04-08 | 2021-02-22 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
-
2013
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en active Application Filing
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/en active
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
-
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
-
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
-
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
-
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
-
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN02324A (no) | ||
| MX2013011721A (es) | Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
| IN2015DN01156A (no) | ||
| NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| WO2010083239A3 (en) | Therapeutic modulation of vaginal epithelium boundary lubrication | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| MX367091B (es) | Una composición farmacéutica o cosmética tópica que comprende un extracto de la baya de la fruta milagrosa (synsepalum dulcificum) para usarse en el tratamiento o la prevención de desórdenes en la piel, mebrana mucosa, cabello, articulaciones y uñas. | |
| GB201213267D0 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| MX2014000567A (es) | Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios. | |
| MX2015003074A (es) | Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| EA201491532A1 (ru) | Фармацевтические композиции для использования в комплексной терапии | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| MX343589B (es) | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. | |
| WO2016108572A3 (ko) | 콜레스테롤 관련 질환의 예방 및 치료용 조성물 | |
| WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth | |
| TN2015000048A1 (en) | Methods of administering rifaximin for weight loss and treatment of obesity |